Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Age \>18; Able to give informed consent~2. Chronic kidney disease, and estimated GFR 15 to 60 ml/min using the abbreviated MDRD equation~3. intact PTH (iPTH) \>120 pg/ml at baseline~4. albumin corrected calcium \> 8.5 mg/dL to \< 10.0 mg/dL at baseline~5. Phosphorus \< 4.6 mg/dL at baseline~6. If on a phosphorus binder; no change in dose within the 4 weeks prior to screening~Exclusion Criteria~1. Receiving any active form of vitamin D within 4 weeks prior to screening (calcitriol, doxercalciferol; paricalcitol; alfacalcidol)~2. Receiving \>50,000 IU per month of ergocalciferol or \> 1000 IU of cholecalciferol per day within the previous 30 days.~3. history of primary HPT~4. On prednisone \> 30 days within the previous 6 months~5. receiving bisphosphonates or calcitonin within the previous 12 months~6. Non-elective hospitalization within the previous 30 days.~7. Expected to initiate dialysis or receive a kidney transplant within the next 6 mo.~8. History of renal or other organ transplant~9. History of parathyroidectomy or previous diagnosis of primary hyperparathyroidism~10. Receiving cinacalcet within 4 weeks prior to screening.~11. An active drug/alcohol dependence or abuse history~12. History of non-compliance with visits or medications that preclude study compliance in the opinion of the investigator~13. Pregnant, or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: EXPERIMENTAL): titrated to achieve 40-60% PTH suppression
- Calcitriol (Type: ACTIVE_COMPARATOR): titrated to achieve 40-60% PTH suppression

Based on this trial design, predict the completion outcome and termination type (if applicable).